Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
The Online Journal of Current Clinical Trials|October 23, 1992
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline resultsL Cashin-Hemphill, D M Kramsch, S P Azen, et al.
The New England Journal of Medicine|October 3, 1996
Esophagitis associated with the use of alendronateP C de Groen, D F Lubbe, L J Hirsch, et al.
Neurology|September 29, 2004
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsyL J Hirsch, D Weintraub, Y Du, et al.
JAMA|April 9, 1997
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study GroupsD B Karpf, D R Shapiro, E Seeman, et al.
Neurology|September 26, 2007
Electrographic seizures and periodic discharges after intracerebral hemorrhageJ Claassen, N Jetté, F Chum, et al.
Brain : a Journal of Neurology|April 3, 2009
Cortical and subcortical networks in human secondarily generalized tonic-clonic seizuresH Blumenfeld, G I Varghese, M J Purcaro, et al.
Brain : a Journal of Neurology|April 3, 2009
Clinical use of ictal SPECT in secondarily generalized tonic-clonic seizuresG I Varghese, M J Purcaro, J E Motelow, et al.
Annals of Internal Medicine|November 15, 1993
Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)D H Blankenhorn, S P Azen, D M Kramsch, et al.
Bone|February 1, 1996
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosisJ P Devogelaer, H Broll, R Correa-Rotter, et al.
Pageof 6